Drug company pricing shenanigans

| 1 Comment

The Wall Street Journal shows how a drug company uses classic tactics to:

A. raise its prices in advance of losing its patent and facing generic competition
B. meantime launching a new "longer-acting" form of the same drug
C setting the new drug's price much lower than the suddenly-inflated old drug's price.
D. setting the hook before generic competition kicks in.
Case in point: Cephalon Inc.'s Provigil narcolepsy drug is now 28% more expensive than in March and 74% more expensive than four years ago.

Meantime, the WSJ reminds us that "In September, Cephalon agreed to plead guilty to one misdemeanor count of violating the U.S. Food, Drug and Cosmetic Act and to pay $444 million to settle federal and state allegations that it promoted Provigil and two other drugs for off-label uses."

1 Comment

This strategy are not NEW to me. As a guy who are working in this industry, I am aware of this what we called "Black Hat" marketing tactics that most of our competitors do.

About this Entry

This page contains a single entry by Gary Schwitzer published on November 18, 2008 3:50 PM.

Saga of the heart sock continues was the previous entry in this blog.

"Science reporting by press release" is the next entry in this blog.

Find recent content on the main index or look in the archives to find all content.

Archives

Pages

Wikio - Top of the Blogs - Health

Add to Technorati Favorites